Martins TD, Annichino-Bizzacchi JM, Romano A, et al. Principal component analysis on recurrent venous thromboembolism [J]. Clin Appl Thromb Hemost, 2019,25：1421673445.

Prandoni P,Noventa F,Ghirarduzzi A,et al. The risk of recur¬rent venous thromboembolism after discontinuing anticoagula¬tion in patients with acute proximal deep vein thrombosis or pulmonary embolism]J]. Hematologica,2007,92(2): 199-205.

Lauber S,Limacher A,Tritschler T,et al. Predictors and out¬comes of recurrent venous thromboembolism in elderly patients Am J Med,2018,131(6):703-7.

Cohen AT,Katholing A,Rietbrock S,et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study[J].Thromb Hae most, 2017,117(1):57-65.

Kearon C,Akl EA,Ornelas J,et al. Antithrombotic therapy for VTE disease：CHEST guideline and expert panel report]J].Chest, 2016,149(2):315-52.

China Council for the promotion of health foundation, throm¬bosis and vascular special fund committee of experts, Pul¬monary Embolism and Pulmonary Vascular Disease Group- Respiratory Society-Chinese Medical Association, Working Com¬mittee of Pulmonary Embolism and Pulmonary Vascular Dis¬ease of Respiratory Physicians Branch of Chinese Medical Doctors Association. Suggestions on prevention and management of venous thromboembolism in hospital[J].Natl Medi J Chin,2018, 98(18)：1383-8.

Rodger MA,Kahn SR,Wells PS,et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy[J].CMAJ,2008,179(5)：417- 26.

Rodger MA,Scarvelis D,Kahn SR,et al. Long-term risk of ve¬nous thrombosis after stopping anticoagulants for a first un - provoked event: a multinational cohort [J ]. Thromb Res, 2016, 143:152-8.

Rodger MA,Le Gal G, Anderson DR,et al. Validating the HER- DOO2 rule to guide treatment duration for women with un¬provoked venous thrombosis: multinational prospective cohort management study [J ].BMJ, 2017,356: jl065.

Couturaud F, Pernod G, Presles E, et al. Six months versus two years of oral anticoagulation after a first episode of un¬provoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial [J ]. Hematologica2019,104(7): 1493-501.

Eichinger S,Heinze G,Jandeck LM,et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model [ J]. Cir¬culation,2010,121 (14)：1630-6.

Eichinger S,Heinze G,Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model[J].J Am Heart Assoc,2014, 3(l)：e467.

Tritschler T,Mean M,Limacher A,et al. Predicting recurrence after unprovoked venous thromboembolism: prospective valida¬tion of the updated Vienna prediction model [J]. Blood,2015, 126(16):1949-51.

Tosetto A,Iorio A,Marcucci M,et al. Predicting disease recur¬rence in patients with previous unprovoked venous throm¬boembolism ： a proposed prediction score(DASH)[J].J Thromb Hemost,2012,10(6): 1019-25.

Tosetto A,Testa S,Martinelli I,et al. External validation of the DASH prediction rule: a retrospective cohort study [J ]. J Thromb Hemost,2017,15(10):1963-70.

MacDonald S,Chengal R,Hanxhiu A,et al.Utility of the DASH score after unprovoked venous thromboembolism; a single cen¬tre studyJ Hematol,2019,185(3):631-3.

Frere C,Benzidia I,Marjanovic Z,et al. Recent advances in the management of cancer-associated thrombosis: new hopes but new challenges [J]. Cancers (Basel), 2019,11(1):71.

Louzada ML,Carrier M, Lazo-Langner A,et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism]J]. Circulation,2012,126(4):448-54.

Astruc N,Ianotto JC,Metges JP,et al. External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis [J]. Eur J Intern Med, 2016,36: ell-el2.

Delluc A,Miranda S,Exter PD,et al. Accuracy of the Ottawa score in risk stratification of recurrent venous thromboem¬bolism in patients with cancer-associated venous thromboem¬bolism ： a systematic review and meta-analysis [J]. Hematolo¬gica, 2020, 105(5):1436-42.

Piran S,Schulman S. Management of recurrent venous throm¬boembolism in patients with cancer: a review [J ]. Thromb Res, 2018,164(Suppl 1)：S172-7.

Gran OV,Braekkan SK,Paulsen B,et al. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism [J ]. J Thromb Hae- most,2017,15(7):1361-7.

Timp JF, B raekkan SK, Lijfering WM, et al. Prediction of re¬current venous thrombosis in all. patients with a first venous thrombotic event: the Leiden Thrombosis Recurrence Risk Prediction model(L-TRRiP)[J].PLoS Med,2019,16(10)：el002883.

Timp JF, Lijfering WM, Flinterman LE, et al. Predictive value of factor VIII levels for recurrent venous thrombosis ： results from the MEGA follow-up study[J].J Thromb Hemost,2015, 13(10)：1823-32.

Jacobsen BK,Eggen AE,Mathiesen EB,et al. Cohort profile: the Tromso Study[J].Int J Epidemiol,2012,41 (4)：961-7.

Ahmad A,Sundquist K,Zoller B,et al. Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism[J]. J Thromb Thrombolysis, 2017,44 (1) ：130-8.

Long B,Koyfman A,Gottlieb M. Risk of recurrent venous thro¬mboembolism and bleeding in cancer patients treated with direct oral anticoagulants versus low-molecular-weight heparin [J].Acad Emerg Med,2020,27(2):170-2.

Albertsen IE,S0gaard M,Goldhaber SZ,et al. Development of sex-stratified prediction models for recurrent venous throm¬boembolism： a Danish nationwide cohort study [J.Thromb Hae- most,2020,120(5):805-14.

Bradbury C,Fletcher K,Sun Y,et al. A randomized controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboem¬bolism (VTE) and postthrombotic syndrome in patients be¬ing treated for a first episode of unprovoked VTE (the Ex¬ACT study) [J] J Hematol,2020,188(6):962-75.

Li HY,Li R,Zhi YR,et al. Study on risk prediction model of in-hospital venous thromboembolism in middle-aged and elder¬ly patient. [J] Chin J Nurs,2020,55(01)：68-73.

Tian LY,Wang LQ,Zeng JQ,et al. Research progress in the risk assessment model of venous thromboembolism in chil- dren：[J].Chin J Nurs,2020,55(3)：462-7.

Shi CL,Zhou HX,Tang YJ,et al. Risk factors for venous thromboembolism recurrence and the predictive value of sim¬ plified pulmonary embolism severity index in medical inpa¬tients [J]. Natl Medi J Chin,2016,96(14):1112-5.

. Cai SN,Zhang YX,Chen X,et al. Research progress of build¬ing a prediction model of critically. ill patients' condition change based on big data[J].Chin J Nurs,2018, 53(11)：1382¬-5.

.Wang X, Liu ZY. Introduction and interpretation of guidelines on thromboprophylaxis in the perioperative period of urologi cal surgery [J]. Chin J Surg, 2018,56(1) ：18-23.

Chinese Medical Association Orthopedic Society. Chinese gui¬delines for the prevention of venous thromboembolism during major orthopedic operations [J]. Chin J Orthopedics,2016(2): 65-71.

Cancer and Thrombosis Expert Committee of Chinese Society of Clinical Oncology. Guidelines for the prevention and treat¬ment of tumor-associated venous thromboembolism (2019 edi- tion)[J]. Chin J Clini Oncolo,2019,46(13)：653-60.

Zhang M,Wang Y,Huang J,et al. Survey of medical staff cognition of the control and treatment of venous thromboem¬bolism at seven general hospitals in Beijing: analysis and countermeasures [J ]. Chin J Hospi Administra, 2018,34 (6): 482-6.

Wang XJ,Xu Y,Chen YP,et al.A multicenter survey of know¬ledge about prevention of venous thromboembolism in nurses [J].Chin J Nurs,2017,52(12):1500-4.